Is this your business? Claim it to manage your IP and profile
The xF+ Liquid Biopsy Panel is an innovative test that detects cancer-related genetic mutations using circulating tumor DNA (ctDNA) from blood samples. This non-invasive assay covers a broad range of 523 genes, allowing for the detection of key genetic signatures associated with various solid tumors. Its design focuses on identifying single nucleotide variants, insertions, deletions, and copy number variations, along with specific gene fusions and MSI-H status.<br/><br/>This test empowers clinicians with real-time insights into tumor dynamics, enabling the tracking of genetic changes over time without the need for repeated tissue biopsies. Such monitoring is crucial for assessing the effectiveness of treatments and for making timely therapeutic decisions, especially in patients with advanced cancer.<br/><br/>The xF+ panel's ability to capture tumor heterogeneity offers a comprehensive snapshot of the genomic landscape of a patient’s cancer, supporting the personalization of treatment strategies. Its high sensitivity and specificity in detecting low-frequency variants make it a powerful tool in ongoing cancer management, ensuring therapies are precisely tailored to each patient's genetic profile.
Tempus xT CDx is a sophisticated cancer profiling tool designed to enhance precision oncology. This assay uses next-generation sequencing to analyze over 648 genes and is specifically crafted to provide actionable genomic data for patients with solid tumors. The xT CDx panel examines tumor samples alongside matched normal samples, such as blood or saliva, to deliver comprehensive mutation profiling. This FDA-approved diagnostic tool also identifies microsatellite instability (MSI) status, offering valuable insights into potential therapeutic paths for cancer treatment.<br/><br/>Tempus xT CDx maximizes the detection of clinically relevant mutations, thereby aligning patients with the most effective targeted therapies. Its robust design aids clinicians in identifying both somatic and germline mutations, enabling a more precise approach to cancer management. Moreover, the integration of MSI status helps in recognizing the responsiveness of tumors to certain immunotherapies, promoting personalized treatment strategies.<br/><br/>The test supports the clinical decision-making process by differentiating actionable variants that practitioners can consider for treatment adjustments. Tailored to meet rigorous clinical guidelines, this assay is a vital component in the treatment continuum, guiding both initial therapy choices and adjustments in ongoing patient management efforts.
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to discover IP, meet vendors and manage your IP workflow!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.
